Table 3.
TM-positive group (N = 76) |
TM-negative group (N = 59) |
|||||||
---|---|---|---|---|---|---|---|---|
Total (N = 135) |
Cancer (N = 41) |
No cancer (N = 35) |
p* | Cancer (N = 9) |
No cancer (N = 50) |
p** | p*** | |
CT, n/N(%) | 131/135 (97.0) | 41/41 (100) | 35/35 (100) | 1 | 9/9 (100) | 46/50 (92.0) | 0.71 | 0.11 |
Region, n/N(%) | ||||||||
Cerebral | 22/131 (16.8) | 10/41 (24.4) | 7/35 (20.0) | 0.86 | 2/9 (22.2) | 3/46 (6.5) | NA | 0.06 |
Cervical | 17/131 (13.0) | 5/41 (12.2) | 3/35 (8.6) | 0.89 | 1/9 (11.1) | 8/46 (17.4) | NA | 0.48 |
Thoracic | 114/131 (87.0) | 35/41 (95.1) | 30/35 (85.7) | 1 | 7/9 (77.8) | 42/46 (91.3) | 0.63 | 0.73 |
Abdomen and pelvis | 113/131 (86.3) | 39/41 (95.1) | 26/35 (74.3) | 0.03 | 9/9 (100.0) | 40/46 (87.0) | 0.20 | 0.73 |
Suspicious findings, n/N(%) | 52/131 (39.7) | 36/41 (87.8) | 3/35 (8.57) | < 1.10 − 4 | 7/9 (77.8) | 6/46 (13.0) | 1 | 0.008 |
Mass, n/N(%) | 40/131 (30.5) | 26/41 (63.4) | 3/35 (8.6) | < 1.10 − 4 | 7/9 (77.8) | 4/46 (8.7) | < 1.10 − 4 | 0.032 |
Suspicious secondary lesion(s), n/N(%) | 27/131 (20.6) | 21/41 (51.2) | 0 | NA | 4/9 (44.4) | 2/46 (4.3) | NA | 0.021 |
Enlarged lymph node(s), n/N(%) | 56/131 (42.8) | 26/41 (63.4) | 11/35 (31.43) | 0.003 | 6/9 (66.7) | 13/46 (28.3) | 0.06 | 0.11 |
Effusion, n/N(%) | 40/131 (30.5) | 19/41 (46.3) | 9/35 (25.7) | 0.06 | 3/9 (33.3) | 9/46 (19.6) | 0.69 | 0.08 |
Thrombosis, n/N(%) | 15/131 (11.5) | 8/41 (19.5) | 2/35 (5.7) | NA | 2/9 (22.2) | 3/46 (6.5) | NA | 0.63 |
Relevant for final diagnosis, n/N(%) | 62/131 (47.3) | 36/41 (87.8) | 8/35 (22.9) | < 10 − 4 | 7/9 (77.8) | 11/46 (23.9) | < 1.10 − 4 | < 1.10 − 4 |
False positive, n/N(%) | 9/131 (6.9) | 0/41 | 3/35 (8.6) | NA | 0/9 | 6/46 (13.0) | NA | 0.26 |
Legends: CT: computed tomography, NA: not applicable
* TM-positive patients with cancer vs. TM-positive patients without cancer
** TM-negative patients with cancer vs. TM-negative patients without cancer
*** TM-positive patients vs. TM-negative patients